{
    "hands_on_practices": [
        {
            "introduction": "Precision in sentinel lymph node (SLN) mapping begins with the meticulous preparation and administration of the tracer. Understanding the relationship between concentration, volume, and mass is not merely an academic exercise; it is a foundational skill for ensuring patient safety and the efficacy of the procedure. This first practice problem focuses on the fundamental calculation of an Indocyanine Green (ICG) dose, a common fluorescent agent, reinforcing the quantitative principles that underpin safe and effective tracer injection .",
            "id": "4508970",
            "problem": "In fluorescence-guided sentinel lymph node mapping for endometrial or vulvar cancer, Indocyanine Green (ICG) is injected into the cervix at multiple sites to facilitate lymphatic visualization. Assume the following scientifically standard and widely used preparation and administration approach: a solution of ICG has a concentration of $1.25$ milligrams per milliliter, and the cervix is injected at $4$ quadrants with equal volume at each site. The injection volume per site is $0.5$ milliliters. Assume no loss of injectate to leakage or degradation at the moment of administration, and that the injected solution is homogeneous.\n\nUsing only fundamental definitions relating concentration, mass, and volume, determine the total ICG dose administered across all injection sites. Round your answer to two significant figures. Express the final dose in milligrams.",
            "solution": "The problem requires the calculation of the total mass of Indocyanine Green (ICG) administered based on given concentration and injection volumes.\n\n### Step 1: Extract Givens\nThe explicit data and conditions provided in the problem statement are:\n-   Concentration of ICG solution, $C$: $1.25$ milligrams per milliliter.\n-   Number of injection sites, $N_{sites}$: $4$ quadrants.\n-   Injection volume per site, $V_{site}$: $0.5$ milliliters.\n-   Condition 1: The volume injected at each site is equal.\n-   Condition 2: There is no loss of injectate to leakage or degradation at the moment of administration.\n-   Condition 3: The injected solution is homogeneous.\n-   Requirement: The final answer must be rounded to two significant figures and expressed in milligrams.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is subjected to validation against the specified criteria.\n\n-   **Scientifically Grounded**: The problem describes a standard clinical procedure for sentinel lymph node mapping. The use of ICG, its concentration ($1.25 \\, \\text{mg/mL}$), the number of injection sites ($4$), and the volume per site ($0.5 \\, \\text{mL}$) are all consistent with established medical practice. The calculation is based on the fundamental definition of concentration ($C = \\frac{m}{V}$), a core principle in chemistry and pharmacology. The problem is scientifically sound.\n-   **Well-Posed**: All necessary information to determine the total mass is provided. The givens are sufficient and lead to a unique solution.\n-   **Objective**: The problem is stated using precise, quantitative language. It is free from subjective claims or ambiguity.\n\nThe problem does not exhibit any of the listed invalidating flaws. It is self-contained, consistent, realistic, and solvable through formal reasoning.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be derived.\n\n### Solution Derivation\nThe fundamental relationship between mass ($m$), concentration ($C$), and volume ($V$) is given by the definition of concentration:\n$$C = \\frac{m}{V}$$\nTo find the mass of a substance in a solution of known concentration and volume, this equation is rearranged to:\n$$m = C \\times V$$\n\nFirst, we must determine the total volume of the ICG solution administered. The problem states there are $N_{sites} = 4$ injection sites, and the volume injected at each site is $V_{site} = 0.5 \\, \\text{mL}$. The total volume, $V_{total}$, is the sum of the volumes at each site. Since the volume is equal at all sites, we can calculate the total volume as:\n$$V_{total} = N_{sites} \\times V_{site}$$\nSubstituting the given values:\n$$V_{total} = 4 \\times 0.5 \\, \\text{mL} = 2.0 \\, \\text{mL}$$\n\nNext, we calculate the total mass of ICG, $m_{total}$, using the total volume $V_{total}$ and the given concentration $C = 1.25 \\, \\frac{\\text{mg}}{\\text{mL}}$.\n$$m_{total} = C \\times V_{total}$$\nSubstituting the values for concentration and total volume:\n$$m_{total} = 1.25 \\, \\frac{\\text{mg}}{\\text{mL}} \\times 2.0 \\, \\text{mL}$$\nPerforming the multiplication:\n$$m_{total} = 2.5 \\, \\text{mg}$$\n\nThe problem requires the final answer to be rounded to two significant figures. The calculated value is $2.5$. The digit '$2$' is significant, and the digit '$5$' is significant. Therefore, the number $2.5$ already has exactly two significant figures. No further rounding is necessary.\n\nThe total dose of ICG administered is $2.5$ milligrams.",
            "answer": "$$\\boxed{2.5}$$"
        },
        {
            "introduction": "While ideal mapping involves clear, concordant signals, the reality of the operating room often presents complex challenges that require sharp critical thinking. A common scenario is discordant mapping, where dual-tracer techniques yield conflicting information, such as a fluorescent-only node and a radioactive-only focus. This exercise  simulates just such a scenario, testing your ability to troubleshoot in real-time by applying the physical principles of each detection method, recognizing potential artifacts like \"shine-through,\" and adhering to an established algorithm to maximize the accuracy of nodal staging.",
            "id": "4508888",
            "problem": "A patient with apparent stage $\\text{I}$ endometrial adenocarcinoma undergoes minimally invasive sentinel lymph node (SLN) mapping using dual tracers: technetium-$99$m radiocolloid injected cervically at $3$ and $9$ o’clock and Indocyanine Green (ICG) for Near-Infrared (NIR) fluorescence. After $\\approx 2$ hours from injection and at the start of pelvic lymphatic exploration, the left pelvis shows the following discordant signals: an ICG-fluorescent node in the obturator fossa with low gamma counts ($\\approx 200$ counts per second), and a nearby external iliac region hot focus with high gamma counts ($\\approx 1500$ counts per second) but no apparent fluorescence. Ambient lights are partially dimmed, and the gamma probe is collimated in standard fashion. There is a cervical injection depot visible on the left. The right pelvis maps normally with a single ICG-positive, gamma-avid node.\n\nStarting from the core definitions of a sentinel node as the first nodal basin receiving lymphatic flow from the primary, the physical basis of detection by gamma scintillation (penetrating photons obeying an inverse-square relationship of detected intensity with source distance) and by NIR fluorescence (excitation-emission limited by tissue absorption following Beer–Lambert behavior), and the widely accepted algorithmic principle that dual-tracer discordance warrants evaluation of both signals before deciding on node harvest, which of the following is the most appropriate immediate troubleshooting sequence and operative decision on the left side to maximize true SLN identification while minimizing false positives?\n\nA. First shield the cervical injection site to reduce gamma shine-through and re-orient the gamma probe to interrogate the hot focus from multiple angles; concurrently optimize NIR imaging by further reducing ambient light, adjusting camera gain and focus, and gently mobilizing overlying fat to decrease path length; confirm that the hot focus corresponds to a discrete nodal structure with a lymphatic pedicle rather than contamination; then harvest both the ICG-positive low-count node and the gamma-avid non-fluorescent node with ex vivo confirmation of gamma counts and NIR signal; if mapping remains discordant or fails unilaterally after optimization, proceed with side-specific lymphadenectomy per guideline.\n\nB. Ignore the ICG-positive node due to its low gamma counts and remove only the hottest gamma focus, attributing the lack of fluorescence to deep location, without further optimization or verification steps.\n\nC. Abandon the current mapping by immediately re-injecting both technetium-$99$m and ICG and restarting the procedure, discarding any nodes currently identified to avoid discordance.\n\nD. Attribute the hot, non-fluorescent focus to cervical injection-site shine-through and avoid removing any node on the left side; proceed only with contralateral mapping, since bilateral mapping is not required when one side is adequate.\n\nE. Clip the lymphatic channel proximal to the fluorescent node to prevent further tracer spread, then increase NIR excitation power and rely exclusively on fluorescence to select the node, setting the gamma probe aside on the left.",
            "solution": "The user requires a critical validation of the provided problem statement, followed by a detailed solution and evaluation of all options.\n\n### Step 1: Extract Givens\n\n-   **Patient Condition**: Apparent stage $\\text{I}$ endometrial adenocarcinoma.\n-   **Procedure**: Minimally invasive sentinel lymph node (SLN) mapping.\n-   **Tracers**:\n    1.  Technetium-$99$m (Tc-99m) radiocolloid, injected cervically at $3$ and $9$ o’clock.\n    2.  Indocyanine Green (ICG), injected cervically for Near-Infrared (NIR) fluorescence.\n-   **Timing**: Pelvic exploration starts $\\approx 2$ hours after injection.\n-   **Findings (Left Pelvis)**:\n    1.  An ICG-fluorescent node in the obturator fossa with low gamma counts ($\\approx 200$ counts per second).\n    2.  A nearby external iliac region hot focus with high gamma counts ($\\approx 1500$ counts per second) but no apparent fluorescence.\n-   **Intraoperative Conditions**:\n    -   Ambient lights are partially dimmed.\n    -   Gamma probe is collimated in standard fashion.\n    -   A cervical injection depot is visible on the left.\n-   **Findings (Right Pelvis)**: Normal mapping with a single ICG-positive, gamma-avid node.\n-   **Stated Principles for Evaluation**:\n    1.  Definition of SLN: The first nodal basin receiving lymphatic flow.\n    2.  Physical Basis of Detection:\n        -   Gamma scintillation (Tc-99m): Penetrating photons, inverse-square law ($I \\propto 1/r^2$).\n        -   NIR fluorescence (ICG): Excitation-emission limited by tissue absorption (Beer–Lambert behavior).\n    3.  Algorithmic Principle: Dual-tracer discordance warrants evaluation of both signals before deciding on node harvest.\n-   **Question**: Identify the most appropriate immediate troubleshooting sequence and operative decision on the left side to maximize true SLN identification while minimizing false positives.\n\n### Step 2: Validate Using Extracted Givens\n\n1.  **Scientifically Grounded**: The problem is firmly grounded in the established medical and physics principles of sentinel lymph node mapping in gynecologic oncology. The tracers (Tc-99m, ICG), detection modalities (gamma probe, NIR camera), anatomical locations, and the phenomenon of discordant mapping are all standard and accurately described. The underlying physics principles cited—the inverse-square law for gamma photon detection and the Beer–Lambert law for optical attenuation—are correct and relevant to the detection technologies. The clinical dilemma is realistic and a frequent point of discussion and research in the field.\n\n2.  **Well-Posed**: The problem is well-posed. It presents a specific clinical scenario with quantitative and qualitative data and asks for the \"most appropriate\" course of action from a list of choices, based on a clear objective (\"maximize true SLN identification while minimizing false positives\"). A single best answer can be determined through logical application of the stated principles and established clinical guidelines.\n\n3.  **Objective**: The language is technical, precise, and free of subjective bias. It describes a set of observations and asks for a decision based on scientific and procedural logic.\n\n4.  **Flaw Checklist**:\n    -   **Scientific/Factual Unsoundness**: None. The scenario is entirely sound.\n    -   **Non-Formalizable/Irrelevant**: None. The problem is a direct and formalizable application of clinical decision-making.\n    -   **Incomplete/Contradictory Setup**: None. The information provided is sufficient. The discordance between the two signals is the core of the problem to be solved, not a contradiction in the problem's setup. The mention of the \"cervical injection depot\" is a critical piece of data that points toward a known potential artifact (shine-through).\n    -   **Unrealistic/Infeasible**: None. This is a realistic and common intraoperative scenario.\n    -   **Ill-Posed/Poorly Structured**: None. A unique best course of action among the options can be identified.\n    -   **Pseudo-Profound/Trivial/Tautological**: None. The problem requires a nuanced understanding of two different technologies, their potential failure modes, and the clinical algorithm designed to reconcile them.\n    -   **Outside Scientific Verifiability**: None. The recommended procedures are based on evidence-based medicine and verifiable physical principles.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **VALID**. It is scientifically sound, well-posed, objective, and presents a realistic and non-trivial clinical challenge. I will proceed with the solution.\n\n### Solution Derivation\n\nThe problem requires determining the optimal sequence of actions to resolve a discordant sentinel lymph node mapping on the left side. The goal is to correctly identify the true sentinel node(s) according to established algorithms, which are designed to maximize sensitivity (minimize false negatives) while applying logical troubleshooting to minimize the removal of non-sentinel tissue (minimize false positives).\n\nThe situation is:\n1.  **ICG-positive node**: A node in the obturator fossa is fluorescent but has low gamma counts ($200$ cps). According to standard dual-tracer algorithms (e.g., the FILM or FIRES trial methodology), any node identified by either tracer is considered a potential SLN. Therefore, this node is a candidate SLN and cannot be ignored. The low counts do not disqualify it.\n2.  **Gamma-avid focus**: A location in the external iliac region is \"hot\" ($1500$ cps) but not fluorescent. There are two primary explanations for this:\n    a.  **True SLN**: It could be a true SLN that is too deep or covered by fat/other tissue for the NIR fluorescence to penetrate and be detected, a limitation dictated by the Beer–Lambert law governing light absorption in tissue.\n    b.  **Artifact**: It could be \"shine-through\" artifact from the nearby cervical injection site. Gamma rays from Tc-99m are highly penetrating, and if the injection depot is close to the pelvic sidewall, the collimated gamma probe can detect this signal, creating a false-positive \"hot spot\". The problem explicitly notes the presence of a \"cervical injection depot visible on the left,\" making this a high-priority possibility to investigate.\n\nA systematic approach must address all these possibilities based on the underlying physics and the clinical algorithm.\n\n1.  **Troubleshoot the Hot, Non-Fluorescent Focus**: The most pressing issue is to determine if the $1500$ cps focus is a true node or an artifact.\n    -   **Shine-Through**: The standard maneuver to rule out shine-through is to shield the injection site (e.g., with a lead-lined instrument, or even a dense, wet laparotomy sponge) and re-measure the counts at the focus. A dramatic drop in counts indicates shine-through. Another technique is triangulation: pointing the probe at the focus from different angles. If the signal is highest when the probe is aimed more towards the cervix, shine-through is likely. If the signal is highest when pointed directly at a specific anatomical point from all angles, a true hot node is likely.\n    -   **Lack of Fluorescence**: Concurrently, the lack of ICG signal should be investigated. This involves optimizing NIR imaging conditions: darkening the room completely, maximizing camera gain without introducing excessive noise, and ensuring optimal camera focus. Most importantly, gentle mobilization or dissection of overlying tissue (fat, peritoneum) can reduce the path length for light, potentially revealing a fluorescent signal from a deeper node.\n    -   **Anatomical Confirmation**: After localization with the probe, the surgeon must visually and tactilely (with instruments) confirm that the focus corresponds to a discrete lymph node structure, ideally with an afferent blue or green lymphatic channel leading to it (though this is not always visible).\n\n2.  **Apply the Discordance Algorithm**: Established guidelines for endometrial cancer SLN mapping are clear: any node that is hot-only, ICG-only, or hot+ICG is to be considered a sentinel node and removed.\n    -   Therefore, the ICG-positive/low-count node should be harvested.\n    -   The gamma-avid/non-fluorescent focus, *if confirmed to be a discrete node after ruling out shine-through*, must also be harvested.\n\n3.  **Ex Vivo Confirmation**: After removal, both specimens should be assessed on the back table, away from the patient. The gamma counts of the hot node are re-checked to confirm its intrinsic radioactivity, definitively separating it from in-situ shine-through. Both nodes are examined with the NIR camera to confirm or disconfirm fluorescence without tissue attenuation.\n\n4.  **Contingency Plan**: If, after this thorough troubleshooting, a definitive SLN cannot be identified on the left side (e.g., the hot spot is confirmed as shine-through and no other nodes are found), the mapping on that side is considered a failure. The standard of care in this situation is to proceed with a side-specific lymphadenectomy to ensure adequate surgical staging.\n\n### Option-by-Option Analysis\n\n**A. First shield the cervical injection site to reduce gamma shine-through and re-orient the gamma probe to interrogate the hot focus from multiple angles; concurrently optimize NIR imaging by further reducing ambient light, adjusting camera gain and focus, and gently mobilizing overlying fat to decrease path length; confirm that the hot focus corresponds to a discrete nodal structure with a lymphatic pedicle rather than contamination; then harvest both the ICG-positive low-count node and the gamma-avid non-fluorescent node with ex vivo confirmation of gamma counts and NIR signal; if mapping remains discordant or fails unilaterally after optimization, proceed with side-specific lymphadenectomy per guideline.**\n-   This option outlines a comprehensive, logical, and step-by-step troubleshooting protocol. It correctly identifies shine-through as a primary concern and describes the standard methods to test for it (shielding, triangulation). It addresses the limitations of NIR imaging (tissue attenuation) and describes appropriate optimization steps. It adheres to the established clinical algorithm of removing all tracer-positive nodes (both the ICG-positive and the gamma-avid one, if confirmed). It includes the critical steps of *ex vivo* confirmation and the correct contingency plan (side-specific lymphadenectomy). This procedure maximizes the chances of identifying the true SLN(s) while minimizing errors.\n-   **Verdict: Correct**\n\n**B. Ignore the ICG-positive node due to its low gamma counts and remove only the hottest gamma focus, attributing the lack of fluorescence to deep location, without further optimization or verification steps.**\n-   This approach is flawed. It violates the core principle of dual-tracer mapping, which dictates that a node positive for *either* tracer is a candidate SLN. Ignoring the ICG-positive node could lead to a false-negative result (missing a true SLN). Furthermore, it accepts the hot focus as a node without any verification, risking the removal of non-nodal tissue due to a shine-through artifact. This is an unsafe and incomplete strategy.\n-   **Verdict: Incorrect**\n\n**C. Abandon the current mapping by immediately re-injecting both technetium-$99$m and ICG and restarting the procedure, discarding any nodes currently identified to avoid discordance.**\n-   This is an illogical and counterproductive action. Re-injection would disrupt the lymphatic drainage pathways, making it impossible to identify the *first* draining node. It would contaminate the field and lead to tracer uptake in secondary and tertiary nodes. The existing discordant data is valuable and must be investigated, as discordance is a known and manageable phenomenon.\n-   **Verdict: Incorrect**\n\n**D. Attribute the hot, non-fluorescent focus to cervical injection-site shine-through and avoid removing any node on the left side; proceed only with contralateral mapping, since bilateral mapping is not required when one side is adequate.**\n-   This option makes an unverified assumption that the hot focus is shine-through. This must be tested, not assumed. It incorrectly suggests ignoring the ICG-positive node that has already been identified. Finally, the premise that \"bilateral mapping is not required when one side is adequate\" is contrary to current standards of care for endometrial cancer, which require bilateral pelvic node assessment for staging. Failure to map one side mandates a full lymphadenectomy on that side. This approach would result in inadequate staging.\n-   **Verdict: Incorrect**\n\n**E. Clip the lymphatic channel proximal to the fluorescent node to prevent further tracer spread, then increase NIR excitation power and rely exclusively on fluorescence to select the node, setting the gamma probe aside on the left.**\n-   This is procedurally incorrect. Clipping lymphatic channels is not a standard part of SLN mapping and could alter drainage patterns. Relying exclusively on one tracer when two were used defeats the purpose of the dual-tracer technique, which is to combine the strengths of both (penetrance of gamma rays and high-contrast visualization of ICG). The gamma-avid focus must be investigated, not ignored.\n-   **Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "The ultimate goal of sentinel lymph node mapping is to inform patient management by accurately staging the disease. The clinical journey does not end with the removal of a node; it culminates in the interpretation of the pathology report and the formulation of an evidence-based adjuvant treatment plan. This final practice problem  challenges you to translate pathologic findings—specifically the size of tumor deposits—into nuanced clinical decisions, applying the standardized classifications of isolated tumor cells (ITCs), micrometastases, and macrometastases to guide appropriate, cancer-specific management for both endometrial and vulvar malignancies.",
            "id": "4508959",
            "problem": "A surgical oncology team performs sentinel lymph node (SLN) mapping and ultrastaging for two patients: one with presumed stage $\\text{I}$ endometrial carcinoma and one with early-stage primary vulvar squamous cell carcinoma. In each patient, pathologic assessment of a single SLN reveals one of the following discrete tumor deposit sizes: $0.15$ mm, $1.2$ mm, and $3.5$ mm. Apply consensus size-based categorization of nodal tumor deposits into isolated tumor cells (ITCs), micrometastases, and macrometastases. Then, reason from the definitions of these categories, the staging principles of lymphatic spread, and the empirically supported treatment paradigms for endometrial and vulvar cancer to infer the adjuvant management implications for each deposit size in each disease context. Which option best states both the correct classification and the most evidence-consistent adjuvant management implications?\n\nA. $0.15$ mm is an ITC, $1.2$ mm is a micrometastasis, and $3.5$ mm is a macrometastasis. In endometrial cancer, ITCs are recorded as $pN0(i+)$ and do not, by themselves, mandate nodal-directed adjuvant therapy; micrometastases and macrometastases upstage to node-positive disease and typically warrant systemic chemotherapy with or without regional radiation based on uterine risk factors and nodal location. In vulvar cancer, ITCs require no further groin treatment; micrometastases can be managed with inguinofemoral radiotherapy without completion lymphadenectomy; macrometastases should prompt completion inguinofemoral lymphadenectomy followed by adjuvant radiotherapy or chemoradiation.\n\nB. $0.15$ mm is a micrometastasis, $1.2$ mm is a macrometastasis, and $3.5$ mm is a macrometastasis. In endometrial cancer, any SLN deposit, including ITCs, upstages to node-positive disease and mandates chemotherapy; in vulvar cancer, any SLN deposit mandates completion lymphadenectomy without adjuvant radiotherapy.\n\nC. $0.15$ mm is an ITC, $1.2$ mm is a micrometastasis, and $3.5$ mm is a macrometastasis. In endometrial cancer, micrometastases can be observed without adjuvant therapy if uterine features are low risk, and macrometastases can be treated with pelvic radiotherapy alone. In vulvar cancer, micrometastases and macrometastases can both be treated with groin radiotherapy alone.\n\nD. $0.15$ mm, $1.2$ mm, and $3.5$ mm are all treated identically as node-positive disease in both endometrial and vulvar cancer: completion lymphadenectomy followed by adjuvant chemoradiation, regardless of deposit size or disease site; size thresholds do not change management.",
            "solution": "### Solution Derivation\nThe problem requires a two-part analysis for each of the two cancer types: first, the correct pathological classification of tumor deposits based on size, and second, the corresponding evidence-based adjuvant management strategy.\n\n**Part 1: Pathological Classification**\nThe American Joint Committee on Cancer (AJCC) defines nodal tumor deposits by size:\n-   **Isolated Tumor Cells (ITCs):** Single cells or small clusters with a greatest dimension $\\le 0.2$ mm.\n-   **Micrometastases:** Tumor deposits with a greatest dimension $> 0.2$ mm but $\\le 2.0$ mm.\n-   **Macrometastases:** Tumor deposits with a greatest dimension $> 2.0$ mm.\n\nApplying these definitions to the given sizes:\n-   $0.15$ mm is an **ITC**.\n-   $1.2$ mm is a **micrometastasis**.\n-   $3.5$ mm is a **macrometastasis**.\nAny correct answer must use this classification.\n\n**Part 2: Adjuvant Management Implications**\n\n**For Endometrial Cancer:**\n-   **ITCs ($0.15$ mm):** These are designated as $pN0(i+)$, do not upstage the patient to node-positive (Stage IIIC), and do not independently warrant adjuvant therapy. Treatment is based on uterine risk factors.\n-   **Micrometastases ($1.2$ mm) and Macrometastases ($3.5$ mm):** Both are considered node-positive disease, upstaging the patient to at least Stage IIIC. This high-risk status typically requires adjuvant systemic chemotherapy, often combined with regional radiation therapy to improve locoregional control.\n\n**For Vulvar Cancer:**\n-   **ITCs ($0.15$ mm):** The risk of further groin disease is extremely low. The standard of care is observation with no further groin treatment.\n-   **Micrometastases ($1.2$ mm):** Based on major clinical trials (e.g., GROINSS-V II), the standard of care is adjuvant inguinofemoral radiotherapy. This avoids the morbidity of a completion lymphadenectomy while maintaining excellent regional control.\n-   **Macrometastases ($3.5$ mm):** The risk of additional nodal disease is high. The standard of care is a completion inguinofemoral lymphadenectomy, typically followed by adjuvant radiotherapy or chemoradiation to reduce the high risk of groin recurrence.\n\n### Option-by-Option Analysis\n\n**A.** This option correctly classifies all three deposit sizes. It accurately describes the distinct management pathways for endometrial cancer (ITCs do not upstage; micro/macrometastases do and warrant systemic therapy +/- radiation) and vulvar cancer (ITCs observed; micrometastases receive radiation alone; macrometastases receive completion lymphadenectomy plus adjuvant therapy). This aligns perfectly with current evidence-based guidelines.\n- **Verdict: Correct**\n\n**B.** This option incorrectly classifies the tumor deposits. It also incorrectly states that ITCs upstage endometrial cancer and that all vulvar deposits mandate completion lymphadenectomy without radiation, which is outdated and inaccurate.\n- **Verdict: Incorrect**\n\n**C.** While the classification is correct, the management described is wrong. It incorrectly suggests that endometrial micrometastases can be observed (they are node-positive disease) and that macrometastases are treated with radiation alone (chemotherapy is standard). It also incorrectly suggests vulvar macrometastases can be treated with radiation alone, omitting the necessary completion lymphadenectomy.\n- **Verdict: Incorrect**\n\n**D.** This option incorrectly claims that all deposits are treated identically, ignoring the critical, size-based risk stratification that defines modern oncologic management. This approach would lead to significant overtreatment of low-volume disease and is contrary to all modern guidelines.\n- **Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}